Liver disease (MASLD / MASH / hepatitis / cirrhosis)

What changes during this transition

Liver disease intersects with peptide therapeutics in three distinct ways, and the editorial honesty differs across each. First, the GLP-1 family is now mainstream MASH medicine. The ESSENCE trial (Sanyal et al., NEJM 2025) reported semaglutide 2.4 mg weekly resolved MASH without fibrosis worsening in 62.9% of patients vs 34.3% placebo, AND improved fibrosis without MASH worsening in 36.8% vs 22.4% — the first Phase 3 GLP-1 trial to meet both endpoints. Tirzepatide's SYNERGY-NASH Phase 2 (Loomba et al., NEJM 2024) reported 44-62% MASH resolution at 52 weeks across dose arms; Phase 3 is underway. These are MASH drugs being adopted into hepatology practice alongside resmetirom (Rezdiffra, FDA-approved March 2024). Second, thymosin alpha-1 is the multi-jurisdictional story this library has to tell honestly. Registered as Zadaxin / Thymalfasin in 30+ countries (China, Italy, India, Korea, Brazil, the Philippines, others) since the 1990s, it carries Tier 1 evidence for chronic hepatitis B in approved markets — meta-analyses of Italian and Chinese cohort trials demonstrate sustained virological response and ALT normalization. Approved HCV and HCC-adjunct indications exist in subsets of jurisdictions. It is NOT FDA-approved in the US — but FDA non-approval is not the world authority on hepatitis therapeutics, and 30+ years of approved-market use abroad with a favorable safety profile is real evidence by any clinical standard. Third, several peptides marketed in wellness-clinic spaces carry liver claims that run well past the evidence. BPC-157 has Sikiric-group rodent hepatic-injury models (CCl4, ischemia-reperfusion, alcohol-injury) but no human liver trials and no human hepatic PK; community framing as 'liver healing' substantially over-reads the rodent literature. Glutathione and IV-glutathione clinics market a 'liver detox' framing that conflates three different molecules — NAC for paracetamol overdose is Tier 1 hepatology emergency medicine; oral and IV glutathione for MASLD have only small studies with modest enzyme-improvement signals. Cirrhosis stage is the load-bearing safety variable across all entries. Compensated cirrhosis (Child-Pugh A) is the context where most decisions are workable; Child-Pugh B requires careful coordination with hepatology; Child-Pugh C and decompensated cirrhosis (ascites, encephalopathy, variceal bleeding, hepatorenal syndrome) are not DIY contexts.